Whitney Lockwood
Family · Crawfordville, FLNPI 1063073336
Payments from drug & device makers
Across 148 payments — averaging $18.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$608
- AstraZeneca$382
- AbbVie$246
- Lilly USA, LLC$234
- Boehringer Ingelheim$192
- Pfizer$162
- plus $922 from 18 others
What the payments were for
- Food & beverage$2,736100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 33 | $608 |
| AstraZeneca | 14 | $382 |
| AbbVie | 18 | $246 |
| Lilly USA, LLC | 24 | $234 |
| Boehringer Ingelheim | 9 | $192 |
| Pfizer | 9 | $162 |
| Exact Sciences | 8 | $140 |
| Abbott | 2 | $136 |
| Amgen | 3 | $99 |
| Phathom Pharmaceuticals, Inc. | 4 | $85 |
| Dexcom, Inc. | 4 | $70 |
| GSK | 3 | $60 |
| IBSA Pharma Inc. | 3 | $52 |
| Sanofi-aventis U.S. LLC | 2 | $49 |
| Tandem Diabetes Care, Inc. | 1 | $45 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $39 |
| Kowa Pharmaceuticals America, Inc. | 2 | $29 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $22 |
| Collegium Pharmaceutical, Inc. | 1 | $21 |
| Ironshore Pharmaceuticals Inc. | 1 | $17 |
| Medtronic | 1 | $16 |
| Merck | 1 | $15 |
| Philips North America LLC | 1 | $15 |
| Sanofi Pasteur Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$104
How this compares
$2,747 in reported general payments places this provider in the 85th percentile of 14,618 family providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 69 | $79,978 |
| MounjaroTirzepatide | 39 | $56,157 |
| JardianceEmpagliflozin | 26 | $39,257 |
| EliquisApixaban | 36 | $35,201 |
| Tresiba Flextouch U-200Insulin Degludec | 30 | $31,728 |
| TrulicityDulaglutide | 17 | $23,948 |
| FarxigaDapagliflozin Propanediol | 16 | $20,710 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 28 | $19,590 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 21 | $12,408 |
| Aimovig AutoinjectorErenumab-Aooe | 11 | $8,240 |
| SymbicortBudesonide/Formoterol Fumarate | 25 | $6,053 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 57 | $5,002 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 12 | $3,207 |
| Atorvastatin Calcium | 234 | $2,852 |
| Humalog Kwikpen U-100Insulin Lispro | 14 | $2,653 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $234 | $80,10656 claims |
| Novo NordiskOzempic | $608 | $79,97869 claims |
| Boehringer IngelheimJardiance | $192 | $39,25726 claims |
| PfizerEliquis | $162 | $35,20136 claims |
| AstraZenecaFarxiga, Symbicort | $382 | $26,76341 claims |
| GSKTrelegy Ellipta | $60 | $19,59028 claims |
| MerckJanumet Xr | $15 | $12,40821 claims |
| AbbVieSynthroid | $246 | $1,57314 claims |
| Sanofi-aventis U.S. LLCLantus | $49 | $1,09415 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 14,618 family providers in Florida.
Other family in Crawfordville
- John HuffakerVenice$8M
- Stephanie MompointMiami$4.5M
- Miguel TrujilloMiami Gardens$4.4M
- Itsel Cardenas RamonMiami$1M
- Lewis HarringtonTampa$954K
- Adam StrosbergFort Lauderdale$859K
- Danielle PharesFt Lauderdale$713K
- David RodriguezHialeah$658K
- Donna OrtizOrlando$417K
- Patrick SzarazMiami$327K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.